Intracranial meningioma epidemiology

• Years of life lost due to central nervous system tumor subtypes in the United States
• Oral contraceptives with progestogens desogestrel or levonorgestrel and risk of intracranial meningioma: national case-control study
• Antiseizure medication in patients with meningioma: a retrospective cohort study on the long-term impact on depression, anxiety and neurocognitive functioning
• Body Mass Index, Physical Activity, and Subsequent Neoplasm Risk Among Childhood Cancer Survivors
• Contributions of cancer treatment and genetic predisposition to risk of subsequent neoplasms in long-term survivors of childhood cancer: a report from the St Jude Lifetime Cohort and the Childhood Cancer Survivor Study
• Epidemiology of adult brain tumors in the Philippine General Hospital from 2018 to 2022: Initial steps to a national brain tumor registry in a lower-middle income country
• Disproportionality analysis of progestogens and estrogens demonstrates increased meningioma risk
• Association between anthropometric factors and meningioma risk: A systematic review and meta-analysis

Meningiomas are the most common primary tumors and account for up to 30% of all central nervous system CNS tumors ¹⁾.

They account for most World Health Organization (WHO) classified Central Nervous System (CNS) tumors in the USA ²⁾.

Although they represent about a third of all the tumors of the central nervous system, knowledge concerning meningioma epidemiology (including incidence data and exploration of the risk factors) remains scarce compared to that of gliomas. A limited number of cancer registry worldwide only record malignant brain tumors, however, their completeness and accuracy have been questioned. Even if comparisons are made difficult due to differences in methodologies, available annual incidence rates (sex- and age-standardized, generally on US or World standard population), provided by population-based registries range from 1.3/100,000 to 7.8/100,000 for cerebral meningiomas. An increase in the incidence of primary brain tumors in general and of meningiomas, in particular, has been observed during the past decades in several countries. It has been suggested that this trend could be artefactual and could be the result of an aging population, improvement in health access and in diagnostic procedures, changes in coding classification for tumors recorded in registries, and/or an increase in the rate of histological confirmation, even in the elderly. All these factors are likely to play a role but they might not fully explain the increase in incidence, observed in most age groups. ³⁾.

Meningiomas are associated with several gonadal steroid hormone-related risk factors and demonstrate a predominance in females